Wermke, M., Gambardella, V., Kuboki, Y., Felip, E., Sanmamed, M. F., Alese, O. B., Sayehli, C. M., Arriola, E., Wolf, J., Villaruz, L. C., Bertulis, J., Studeny, M., Bouzaggou, M., Fang, X., Morgensztern, D. (2025). Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-00363